What happened with CV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
CapsoVision helps gastroenterologists examine the small bowel using a capsule that patients swallow. CapsoCam Plus captures panoramic video and stores it inside the capsule, rather than transmitting it to a patient-worn recorder. Patients must retrieve the capsule after it passes. With CapsoCloud, they return it to a company facility for video processing, and clinicians review the video remotely; CapsoView lets providers download and review the data locally.
All current revenue comes from the CapsoCam Plus small-bowel business, mainly capsule sales. Most sales are in the U.S., where CapsoVision primarily sells directly to clinics and hospitals. Cloud video delivery and physician video-reading services provide a smaller revenue stream. CapsoVision invoices providers, not insurers; providers receive reimbursement that includes the capsule cost, so demand depends partly on whether that reimbursement adequately covers the examination.
Outside the U.S., sales mainly go through distributors. Aureliance, its authorized EU and EEA agent and importer, supplies a significant share of its EU business. Production also depends on single-source components: lens modules from Largan, image sensors from Toshiba, and custom chips from Moai Electronics/Speedbridge. Foreign data-privacy and access rules mean providers outside the U.S. primarily use CapsoView rather than CapsoCloud.
CapsoVision is developing CapsoCam Colon to examine the colon, with automated polyp detection and technology to measure polyp size. This is a planned expansion, not a current revenue source: sales require applicable FDA or EU clearance and satisfaction of related conditions.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
CapsoVision’s results depend on adoption of capsule endoscopy covered by reimbursement amid competition from IntroMedic, JinShan and Ankon, and on critical components supplied solely by Largan, Toshiba and Moai/Speedbridge.
Medtronic competes for CapsoVision’s customers by selling PillCam capsule endoscopy systems to the gastroenterology practices and hospitals that buy CapsoCam capsules. Watch Medtronic’s exclusive supply arrangements with some larger GI practices and hospitals, particularly in the U.S. Northeast: these can last up to three years and limit CapsoVision’s access to those buyers.
CapsoVision, Inc. earningsThis company
CapsoVision’s report will show whether clinics and hospitals are buying enough capsules and related services to cover their costs and support a business that is still loss-making.
Read revenue growth alongside gross profit, the amount left after product and service costs. Growth in both would show that clinic and hospital purchases are bringing in more to fund operating expenses; revenue growth without matching gross-profit growth would mean costs are absorbing the added sales, leaving losses and the need for outside funding central.
Medtronic plc earningsMDT
Medtronic’s report will show how its PillCam capsule-endoscopy business is doing with the gastroenterology practices and hospitals that also buy from CapsoVision.
Watch Medtronic’s capsule-endoscopy business and its exclusive supply arrangements with larger GI practices and hospitals. A stronger business, especially with those arrangements expanding or continuing, would point to tougher competition for shared buyers and potentially less access for CapsoVision; a weaker business would suggest less pressure through this channel, but would not establish CapsoVision’s own sales.
